I keep an eye on the number of recruiting sites. The March presentation, slide 17, shows a planned number of recruiting sites at 60.
https://ir.outlooktherapeutics.com/static-files/cfa0c7ae-7b5e-4500-b21f-cc1a2243d2aa
As of the latest clinical trial update, March 29th, the number of sites was 45. 15 to go, or at the same cadence, about another month (45 sites in the first three months).
With the March presentation, the FDA timeline is in keeping with the previous PRs and presentations. And OTLK has a history of following timelines. So even if it does not unfold exactly as planned, I expect the timeline to be pretty close, maybe a month off but not 4 months for instance.
The rest of the presentation looks similar to previous ones, with more of a focus on European activities and money raises.
Best of luck with your investments!
Recent OTLK News
- Outlook Therapeutics® to Present at the Retina World Congress 2024 • GlobeNewswire Inc. • 05/02/2024 01:05:00 PM
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase • GlobeNewswire Inc. • 04/29/2024 01:00:00 PM
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million • GlobeNewswire Inc. • 04/15/2024 08:15:00 PM
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD • GlobeNewswire Inc. • 03/22/2024 11:35:35 AM
- Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million • GlobeNewswire Inc. • 03/18/2024 09:10:05 PM
- Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 03/12/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:18:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:11:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:08:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:16:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:10:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:40:14 PM
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update • GlobeNewswire Inc. • 02/14/2024 01:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/08/2024 12:00:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 11:59:42 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/31/2024 09:01:44 PM
- Outlook Therapeutics® Doses First Subject in NORSE EIGHT • GlobeNewswire Inc. • 01/31/2024 01:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/29/2024 10:00:29 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 11:02:07 AM
- Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/22/2023 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:15:27 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM